Lexology July 16, 2024
During this session, the panelists discussed the current market outlook for CROs and the key differentiators making them attractive to private equity investors, such as therapeutic area (TA) specialization, their ability to ensure diversity in clinical trials and the integration of artificial intelligence (AI) into their value offerings. They also discussed how the expectations of CRO customers – primarily large pharmaceutical companies – are rising, with a renewed focus on speed and quality in trial execution.
Session panelists:
- Paul Gadiock, Partner, McDermott Will & Emery
- Jeanne Hecht, CEO and Chairwoman of the Board, Lexitas
- John Kerins, Managing Director, Cain Brothers
- Natasha Latif, Principal, The Vistria Group
- Justin Sabet-Peyman, Partner and Deal Team Leader, Patient Square Capital
- Dee Anna Smith,...
Today's Sponsors
Today's Sponsor